A culture medium and culture method for inducing directional differentiation of human pluripotent stem cells into ameloblasts
By using a specific culture medium combination to gradually induce human pluripotent stem cells to differentiate into ameloblasts, the problems of low efficiency and insufficient differentiation in existing technologies have been solved, achieving efficient and stable ameloblast induction and large-scale regeneration of ameloblasts.
Patent Information
- Application Number
- CN202411304398.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-09-19
AI Technical Summary
Existing methods for inducing human pluripotent stem cells to differentiate into ameloblasts are inefficient, difficult to separate, and do not achieve sufficient differentiation, making it impossible to regenerate ameloblasts in large quantities.
A culture medium combination comprising culture medium I, culture medium II, and culture medium III is provided, which induces human pluripotent stem cells to differentiate into ameloblasts by gradually replacing culture medium I, II, and III with specific small molecule factors. The formulation includes components such as DMEM/F12, knockout serum substitute, L-glutamine, non-essential amino acids, penicillin-streptomycin bispecific antibody, and BMP4 protein.
This method enables efficient and economical in vitro induction of human pluripotent stem cells into ameloblasts with short differentiation time, good reproducibility, and stable induction effect. The obtained ameloblasts express ameloblast markers and have the same polarization morphology as in vivo, which can be used for large-scale regeneration of ameloblasts.
Smart Images

Figure CN118813525B_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of culture medium development and application, and specifically relates to a culture medium and a culture method for inducing the directed differentiation of human pluripotent stem cells into ameloblasts. Background Art
[0002] Tooth enamel is located on the surface of teeth and is the hardest tissue in the human body. It has functions such as beauty, chewing, and protecting teeth. However, tooth enamel is often damaged due to caries, trauma, genetic defects, etc. During tooth development, ameloblasts are responsible for producing enamel, but they are lost after human teeth erupt, resulting in the inability of tooth enamel to regenerate after damage, and a lack of cell resources in the human body to study enamel development and genetic mutations.
[0003] Human pluripotent stem cells can be obtained from human adult cells through reprogramming and can differentiate into any type of cell in adult tissues, providing excellent "seed cells" for ameloblast regeneration. However, the development and differentiation cycle of ameloblasts is relatively long and the regulatory factors are relatively complex. More than 100 biological factors have been found to be involved in the regulation of ameloblast development, but the "formula" that controls ameloblast differentiation is still not completely clear. At present, the existing technologies for inducing human pluripotent stem cells to differentiate into ameloblasts include: (1) co-culture with mouse tooth germ mesenchyme; (2) co-culture with human dental pulp stem cells; (3) use of mouse-derived ameloblast conditioned medium.
[0004] However, the induction strategies in the existing technologies have the following shortcomings: (1) The components that induce human pluripotent stem cells to differentiate into ameloblasts are still unclear, and it is impossible to efficiently and massively induce human pluripotent stem cells to differentiate into ameloblasts; (2) After inducing ameloblasts using co-culture technology, it is impossible to separate ameloblasts from mixed cells; (3) Ameloblasts induced in vitro cannot reproduce the polarized morphology of ameloblasts in vivo, and the degree of differentiation is insufficient.
[0005] In recent years, biological small molecules have been favored in the field of directed differentiation of pluripotent stem cells. Compared with biological proteins, they are inexpensive and easy to store, which can greatly reduce the cost of use and are more conducive to promotion and application. Compared with transgenic technology, they are safer, simpler, and can be quantified and adjusted, so they are widely used. However, the small molecules that control the differentiation of human pluripotent stem cells into ameloblasts are still unclear. How to use small molecules with clear ingredients to efficiently, economically, and quickly induce the differentiation of human pluripotent stem cells into ameloblasts is still a major challenge. There is an urgent need to develop an ameloblast induction medium and method. Summary of the invention
[0006] Based on this, an embodiment of the present application provides a culture medium and a culture method for inducing the directed differentiation of human pluripotent stem cells into ameloblasts.
[0007] On the one hand, the present application provides a culture medium for inducing directed differentiation of human pluripotent stem cells into ameloblasts, comprising culture medium I, culture medium II and culture medium III;
[0008] The culture medium I comprises DMEM / F12, knockout serum replacement, L-glutamine, non-essential amino acids, penicillin-streptomycin double antibody, SB431542 and BMP4 protein;
[0009] The culture medium II comprises DMEM / F12, epidermal growth factor, basic fibroblast growth factor, B27 additive, penicillin-streptomycin double antibody, BMP4 protein, retinoic acid and lithium chloride;
[0010] The culture medium III comprises DMEM / F12, fetal bovine serum, sodium β-glycerophosphate, vitamin C, calcium chloride, penicillin-streptomycin double antibody, epidermal growth factor, transforming growth factor β1 and lithium chloride.
[0011] In one embodiment, the culture medium I comprises DMEM / F12 culture medium and 15v / v%~20v / v% knockout serum replacement, 1.5mM~2.5mM L-glutamine, 0.8×10 -4 M~1.2×10 -4 M non-essential amino acids, 0.5v / v%~1.0v / v% penicillin-streptomycin dual antibody, 10μM~20μM SB431542 and 10ng / mL~25ng / mL BMP4 protein.
[0012] In one embodiment, the culture medium II comprises DMEM / F12 culture medium and 15ng / mL~25ng / mL epidermal growth factor, 20ng / mL~30ng / mL basic fibroblast growth factor, 1.0v / v%~2.0v / v% B27 additive, 0.5v / v%~1.0v / v% penicillin-streptomycin double antibody, 10ng / mL~25ng / mL BMP4 protein, 0.5μM~1.0μM retinoic acid and 18mM~22mM lithium chloride.
[0013] In one embodiment, the culture medium III comprises DMEM / F12 basal culture medium and 8v / v%~12v / v% fetal bovine serum, 10mM~20mM sodium β-glycerophosphate, 45μg / mL~55μg / mL vitamin C, 1.5mM~2.5mM calcium chloride, 0.5v / v%~1.0v / v% penicillin-streptomycin double antibody, 8ng / mL~12ng / mL epidermal growth factor, 2.5ng / mL~3.5 ng / mL transforming growth factor β1 and 14mM~16mM lithium chloride.
[0014] On the other hand, the present application provides a method for inducing human pluripotent stem cells to differentiate into ameloblasts, comprising: using the culture medium for inducing human pluripotent stem cells to differentiate into ameloblasts to culture human pluripotent stem cells.
[0015] In one embodiment, the method comprises: culturing human pluripotent stem cells in a basal medium for 0.5 to 1 day; changing to medium I for culturing for 2 to 2.5 days, then changing to medium II for culturing for 2.5 to 3 days; and finally changing to medium III for culturing for 5 to 6 days to obtain ameloblasts;
[0016] The basal culture medium contains mTeSR™1 medium and Y27632.
[0017] In one embodiment, the human pluripotent stem cells further include the steps of pre-culture, digestion and passaging before being cultured in the basal medium.
[0018] In one embodiment, the human pluripotent stem cells are cultured in a basal medium for 2 to 8 generations, with a cell density of 60% to 70% and a cell differentiation ratio of <5%.
[0019] In one embodiment, the digestion step includes: adding cell digestion solution to dissociate human pluripotent stem cells in the basic culture medium, and collecting the cell suspension.
[0020] In one embodiment, the culture method has one or more of the following technical features:
[0021] (1) Change the culture medium every 1 to 2 days during the culture process;
[0022] (2) At 37°C, 5% CO 2 Cultivated under conditions of
[0023] (3) Cultivating human pluripotent stem cells in a culture vessel coated with Matrigel;
[0024] (4) The subculturing step includes inoculating the cell suspension into a culture vessel coated with matrix gel at a subculturing ratio of 1:10 to 1:15. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the technical solutions in the embodiments of the present application and to more completely understand the present application and its beneficial effects, the following is a brief introduction to the drawings required for the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present application, and those skilled in the art can obtain other drawings based on these drawings without creative work.
[0026] Figure 1Schematic diagram of the induction of HPSCs to gradually differentiate into ameloblasts; medium I is the surface ectoderm cell induction medium; medium II is the dental epithelial cell induction medium; medium III is the ameloblast induction medium;
[0027] Figure 2 The results of the optimization experiment of the surface ectoderm cell induction medium (medium I);
[0028] Figure 3 The results of the optimization experiment of dental epithelial cell induction medium (medium II);
[0029] Figure 4 The results of the optimization experiment of ameloblast induction medium (medium III);
[0030] Among them, cell pluripotency marker: OCT4; surface ectoderm marker: KRT18 and ΔNp63, neuroectoderm marker: SOX1, mesoderm marker: Brachyury, endoderm marker: FOXA2; dental epithelial cell marker: KRT14 and p75; ameloblast marker: Tuftelin, AMBN and AMELX. DETAILED DESCRIPTION
[0031] Below in conjunction with embodiment and example, the application is further described in detail.It should be understood that these embodiments and examples are only used to illustrate the application and are not used to limit the scope of the application, and the purpose of providing these embodiments and examples is to make the understanding of the disclosure of the application more thorough and comprehensive.It should also be understood that the application can be implemented in many different forms, is not limited to the embodiment and example described herein, and those skilled in the art can make various changes or modifications without violating the connotation of the application, and the equivalent form obtained also falls within the protection scope of the application.In addition, in the description below, a large number of specific details are given in order to provide a more comprehensive understanding of the application, and it should be understood that the application can be implemented without one or more of these details.
[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
[0033] the term
[0034] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:
[0035] The terms "and / or", "or / and", and "and / or" used in this article include any one of two or more related listed items, and also include any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").
[0036] In the present application, "plurality", "multiple", "multiple times", "multiples", etc., unless otherwise specified, refer to a number greater than 2 or equal to 2. For example, "one or more" means one or greater than or equal to two.
[0037] As used herein, "combination thereof", "any combination thereof", "any combination thereof" etc. include all suitable combinations of any two or more of the listed items.
[0038] Herein, the “suitable” mentioned in “suitable combination”, “suitable method”, “any suitable method”, etc., shall be based on the ability to implement the technical solution of this application, solve the technical problems of this application, and achieve the expected technical effects of this application.
[0039] In the present application, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present application.
[0040] In this application, "optionally", "optional", and "optional" mean optional or dispensable, that is, any one of the two parallel schemes of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent.
[0041] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0042] In the present application, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to the integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In this article, it is equivalent to directly listing each integer, such as t is an integer selected from 1 to 10, indicating that t is any integer selected from the integer group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all sub-ranges included therein.
[0043] The temperature parameters in this application, unless otherwise specified, are allowed to be either constant temperature treatment or to vary within a certain temperature range. It should be understood that the constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. Fluctuations within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are allowed.
[0044] In the present application, % (w / w) and wt% both represent weight percentage, % (v / v) refers to volume percentage, and % (w / v) refers to mass volume percentage.
[0045] All documents mentioned in this application are cited as references in this application, just as each document is cited as reference separately. Unless they conflict with the invention purpose and / or technical solution of this application, the cited documents involved in this application are cited with all contents and all purposes. When the cited documents are involved in this application, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the cited documents are involved in this application, the examples and preferred methods of the cited relevant technical features can also be incorporated into this application as references, but are limited to the implementation of this application. It should be understood that when the cited content conflicts with the description in this application, the present application shall prevail or be modified adaptively according to the description of this application.
[0046] The term "HPSCs" human pluripotent stem cells, human pluripotent stem cells, human pluripotent stem cells (Pluripotent Stem Cells, PSC) are a type of cell with self-renewal and multidirectional differentiation potential, which can differentiate into almost all types of cells. Pluripotent stem cells can differentiate into almost all types of cells, but cannot form accessory supporting tissues such as placenta and umbilical cord. They have the basic characteristics of self-renewal and multidirectional differentiation.
[0047] The term "KSR" knockout serum replacement, knockout serum replacement, knockout serum replacement (KSR) is a synthetic protein source that is widely used in in vitro cell culture, especially in the culture of pluripotent stem cells. KSR is a serum-free product used to replace fetal bovine serum to promote the growth of undifferentiated pluripotent stem cells. It can be used for routine maintenance and induction of growth and differentiation of human or non-human primate embryonic stem cells (ESCs) and pluripotent stem cells (iPSCs).
[0048] Term "BMP4" bone morphogenetic protein 4, Bone morphogenetic protein 4, Bone morphogenetic protein 4 (BMP-4) is a pleiotropic ligand protein that belongs to the TGFβ (transforming growth factor β) family. BMP-4 is involved in the vascular system circulation and can activate receptors on vascular cells. It plays a key role in vascular and valvular homeostasis, which is an important process in embryonic development. BMP-4 increases plaque formation through its pro-inflammatory and pro-atherogenic effects, promotes oxidative stress, endothelial dysfunction and osteogenic differentiation.
[0049] The term "b-FGF" stands for basic fibroblast growth factor; basic fibroblast growth factor (bFGF) is a multifunctional cell growth factor with multiple biological functions and important roles. bFGF is a key growth factor in stem cell culture and is very important for maintaining the undifferentiated state of cells. In particular, in human stem cell culture, bFGF is needed to inhibit cell differentiation.
[0050] The term "EGF" epidermal growth factor, epidermal growth factor, epidermal growth factor (EpidermalGrowth Factor, EGF) is a multifunctional growth factor with a wide range of biological effects. EGF can stimulate the proliferation of a variety of cells and the metabolism of normal epidermal cells.
[0051] The term "RA" retinoic acid, retinoic acid, retinoic acid (RA), also known as vitamin A acid or retinoic acid, is a metabolite of vitamin A, has important biological activity, and plays a key role in cell growth, differentiation and organ formation. Retinoic acid is a natural activator of the nuclear receptor RAR (Retinoic Acid Receptor), which has the function of regulating the activation and expression of messenger RNA in the cell nucleus. It regulates the expression of target genes by interacting with RAR and RXR (Retinoid X Receptor).
[0052] The term "TGF-β1" is a pleiotropic cytokine in the transforming growth factor β superfamily with a wide range of biological functions. TGF-β1 plays an important role in cell proliferation, differentiation, immune regulation and maintaining body homeostasis. It binds to receptors on the cell surface and activates downstream signaling pathways, thereby regulating cell behavior.
[0053] The term "penicillin-streptomycin double antibiotic" is commonly referred to as "double antibiotic". It is commercially available and is an antibiotic mixture widely used in cell culture to prevent microbial contamination. This mixture contains two antibiotics, penicillin and streptomycin. Penicillin mainly targets Gram-positive bacteria and works by interfering with the synthesis of bacterial cell walls; while streptomycin is effective against both Gram-negative and Gram-positive bacteria. It inhibits bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome. The combined use of these two antibiotics can cover a wider antibacterial spectrum and effectively prevent most bacterial contamination.
[0054] One of the embodiments of the present application provides a culture medium for inducing the directed differentiation of human pluripotent stem cells into ameloblasts, comprising culture medium I, culture medium II and culture medium III.
[0055] Medium I contained DMEM / F12, knockout serum replacement, L-glutamine, nonessential amino acids, penicillin-streptomycin, SB431542, and BMP4 protein.
[0056] Medium II contains DMEM / F12, epidermal growth factor, basic fibroblast growth factor, B27 supplement, penicillin-streptomycin double antibody, BMP4 protein, retinoic acid and lithium chloride.
[0057] Medium III contains DMEM / F12, fetal bovine serum, sodium β-glycerophosphate, vitamin C, calcium chloride, penicillin-streptomycin, epidermal growth factor, transforming growth factor β1, and lithium chloride.
[0058] In a specific example, medium I comprises DMEM / F12 medium and 15 v / v% to 20 v / v% knockout serum replacement, 1.5 mM to 2.5 mM L-glutamine, 0.8×10 -4 M~1.2×10 -4 M non-essential amino acids, 0.5v / v%~1.0v / v% penicillin-streptomycin dual antibody, 10μM~20μM SB431542 and 10ng / mL~25ng / mL BMP4 protein.
[0059] In a specific example, culture medium II contains DMEM / F12 culture medium and 15ng / mL~25ng / mL epidermal growth factor, 20ng / mL~30ng / mL basic fibroblast growth factor, 1.0v / v%~2.0v / v% B27 additive, 0.5 v / v%~1.0v / v% penicillin-streptomycin double antibody, 10ng / mL~25ng / mL BMP4 protein, 0.5μM~1.0μM retinoic acid and 18mM~22mM lithium chloride.
[0060] In a specific example, culture medium III comprises DMEM / F12 basal culture medium and 8v / v%~12v / v% fetal bovine serum, 10mM~20mM sodium β-glycerophosphate, 45μg / mL~55μg / mL vitamin C, 1.5mM~2.5mM calcium chloride, 0.5v / v%~1.0v / v% penicillin-streptomycin double antibody, 8ng / mL~12ng / mL epidermal growth factor, 2.5ng / mL~3.5ng / mL transforming growth factor β1 and 14mM~16mM lithium chloride.
[0061] On the other hand, the present application provides a method for inducing human pluripotent stem cells to differentiate into ameloblasts, comprising: using the culture medium for inducing human pluripotent stem cells to differentiate into ameloblasts to culture human pluripotent stem cells.
[0062] In a specific example, the method comprises: culturing human pluripotent stem cells in a basal medium for 0.5 to 1 day; changing to medium I for culturing for 2 to 2.5 days, and then changing to medium II for culturing for 2.5 to 3 days; and finally changing to medium III for culturing for 5 to 6 days to obtain ameloblasts;
[0063] The basal culture medium contains mTeSR™1 medium and Y27632.
[0064] The culturing step includes culturing human pluripotent stem cells in a culture container coated with Matrigel, adding mTeSR™1 culture medium, and culturing. Specifically, HPSCs are cultured in a 6-well plate coated with Matrigel, and mTeSR™1 culture medium is added, with 2 mL of culture medium per well, and placed in an incubator for cell culture (37°C, 5% CO 2 The medium was changed daily, and cells were passaged when the cell density reached 60%-70%.
[0065] In a specific example, the human pluripotent stem cells further include the steps of pre-culture, digestion and passaging before being cultured in the basal medium.
[0066] Specifically, add 1 mL of PBS without calcium and magnesium to each well of a 6-well plate, aspirate and discard; add 1 mL of GentleCell Dissociation Reagent (mild separation solution), incubate at room temperature (25°C) for 2 minutes, aspirate and discard; add 1 mL of DMEM / F12, aspirate and discard; add 2 mL of mTeSR™1 culture medium (containing 10 μM Y27632), use a cell scraper to free HPSCs, and collect the cell suspension into a 15 mL centrifuge tube.
[0067] In a specific example, the human pluripotent stem cells have a generation number of 2 to 8 before being cultured in a basic culture medium, a cell density of 60% to 70%, and a cell differentiation ratio of <5%.
[0068] In a specific example, the digestion step includes: adding cell digestion solution, dissociating human pluripotent stem cells in the basic culture medium, and collecting cell suspension.
[0069] In a specific example, the culture method has one or more of the following technical features:
[0070] (1) Change the culture medium every 1 to 2 days during the culture process;
[0071] (2) At 37°C, 5% CO 2 Cultivated under conditions of
[0072] (3) Cultivating human pluripotent stem cells in a culture vessel coated with Matrigel;
[0073] (4) The subculturing step includes inoculating the cell suspension into a culture vessel coated with matrix gel at a subculturing ratio of 1:10 to 1:15.
[0074] Based on the principle of ameloblast development, the present application provides a culture medium for inducing the directed differentiation of human pluripotent stem cells into ameloblasts, including culture medium I, culture medium II, and culture medium III, which use biological molecules with clear components to induce HPSCs to differentiate into surface ectoderm cells, dental epithelial cells, and ameloblasts in sequence. The induced ameloblasts not only express ameloblast markers, but also have a cell polarization morphology. For the first time, HPSCs are induced to differentiate into polarized ameloblasts in vitro, which is consistent with the in vivo phenotype and can be used to regenerate ameloblasts in large quantities. The induction effect of the present application is stable and reliable, the induction components are clear, and the effect of HPSCs directed ameloblast differentiation is stable and reproducible.
[0075] Furthermore, the induction step of the present application is simple, and only the induction solution needs to be replaced regularly. There is no need to form embryoid bodies, and no co-culture technology is required. The induction and screening steps can be completed in a cell-adherent state. Secondly, the induction time of the present application is short and efficient. The present application only takes 11 days to induce ameloblasts from HPSCs, with a short induction time and an efficient method. At the same time, the induction effect of the present application is more intuitive and easy to monitor. Since the cell morphology at each induction stage is different and has its own characteristics, the differentiation state can be intuitively monitored through cell morphology.
[0076] The embodiments of the present application will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.
[0077] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.
[0078] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution. The execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application. Example 1
[0079] 1. Cultivation process
[0080] 1. Culture of HPSCs
[0081] HPSCs were cultured in Matrigel-coated 6-well plates, and mTeSR™1 culture medium was added, 2 mL of culture medium per well, and placed in an incubator for cell culture (37°C, 5% CO 2The medium was changed daily, and cells were passaged when the cell density reached 60%-70%.
[0082] 2. Digestion and Passaging of HPSCs
[0083] (1) Cell digestion: Add 1 mL of PBS without calcium and magnesium to each well of a 6-well plate, aspirate and discard; add 1 mL of GentleCell Dissociation Reagent, incubate at room temperature (25°C) for 2 min, aspirate and discard; add 1 mL of DMEM / F12, aspirate and discard; add 2 mL of mTeSR™1 culture medium (containing 10 μM Y27632), use a cell scraper to free HPSCs, and collect the cell suspension into a 15 mL centrifuge tube.
[0084] (2) Cell passaging: Inoculate the cell suspension into a new, Matrigel-coated 6-well plate at a passaging ratio of 1:10-1:15. The culture medium used for passaging is mTeSR™1 culture medium (containing 10 μM Y27632). Change the medium the next day and use mTeSR™1 culture medium without Y27632 for cell culture. Change the medium daily until the cell density reaches 60%-70%, at which time the cells can be passaged.
[0085] (3) Induction scheme for gradual differentiation of HPSCs into ameloblasts
[0086] HPSCs of passages 2 to 8 are used in ameloblast induction experiments, requiring a cell density of 60% to 70% and a cell differentiation ratio of less than 5%. The specific schematic diagram of the induction of HPSCs gradually differentiating into ameloblasts is shown in the figure. Figure 1 shown.
[0087] Medium I (surface ectoderm cell induction medium): DMEM / F12 medium with 20v / v% knockout serum replacement, 2mM L-glutamine, 1.0×10 -4 M non-essential amino acids, 0.5v / v% penicillin-streptomycin double antibody, 10μM SB431542 and 10ng / mL BMP4 protein.
[0088] Culture medium II (dental epithelial cell induction medium): DMEM / F12 culture medium plus 20 ng / mL epidermal growth factor, 25 ng / mL basic fibroblast growth factor, 2.0 v / v% B27 supplement, 1.0 v / v% penicillin-streptomycin double antibody, 12.5 ng / mL BMP4 protein, 1.0 μM retinoic acid and 20 mM lithium chloride.
[0089] Culture medium III (ameloblast induction medium): DMEM / F12 basal medium with 10 v / v% fetal bovine serum, 20 mM sodium β-glycerophosphate, 50 μg / mL vitamin C, 2.0 mM calcium chloride, 1.0 v / v% penicillin-streptomycin double antibody, 10 ng / mL epidermal growth factor, 3.0 ng / mL transforming growth factor β1 and 15 mM lithium chloride.
[0090] Day 0: Cell digestion steps were the same as before, and the cell suspension was inoculated into a new, Matrigel-coated 6-well plate at a seeding ratio of 1:3. The culture medium used was mTeSR™1 culture medium supplemented with 10μM Y27632.
[0091] Day 1: Start the stage of surface ectoderm cell induction (stage 1). Aspirate the old culture medium and add medium I, including DMEM / F12, 20% KSR (knockout serum replacement), 2mM L-glutamine, 1×10 -4 M non-essential amino acids, 0.5% penicillin-streptomycin, 10 μM SB431542 and 10 ng / mL BMP4.
[0092] Day 2: Aspirate and discard the old culture medium and replace with new culture medium I.
[0093] Day 3: Start the dental epithelial cell induction stage (stage 2). Aspirate and discard the old culture medium, add culture medium II, which contains DMEM / F12, 20ng / mL EGF (epidermal growth factor), 25ng / mL b-FGF (basic fibroblast growth factor), 2% B27 supplement, 1% penicillin-streptomycin double antibody, 12.5ng / mL BMP4, 1μM RA (retinoic acid) and 20mM LiCl (lithium chloride).
[0094] Day 4: Aspirate and discard the old culture medium and replace with new culture medium II.
[0095] Day 5: Aspirate and discard the old culture medium and replace with new culture medium II.
[0096] Day 6: Start the ameloblast induction stage (stage 3). Aspirate and discard the old culture medium, and add culture medium III, which contains DMEM / F12, 10 v / v% fetal bovine serum, 20mM sodium B-glycerophosphate, 50ng / mL vitamin C, 2mM calcium chloride, 15v / v% penicillin-streptomycin double antibody, 10ng / mL EGF, 3ng / mL TGF-β1 (transforming growth factor β1) and 15mM LiCl.
[0097] Day 7: Aspirate and discard the old culture medium and replace with new culture medium III.
[0098] Day 9: Aspirate and discard the old culture medium and replace with new culture medium III.
[0099] Day 11: Ameloblast induction is completed and polarized ameloblasts can be obtained.
[0100] 2. Verification of optimization results of different culture medium formulas
[0101] (1) Methods:
[0102] 1. Cell morphology
[0103] The cell morphology was observed and photographed using an optical microscope.
[0104] 2. Real-time quantitative PCR
[0105] According to the induction scheme, samples were collected at different induction stages, washed once with PBS, and intracellular RNA was extracted by TRIZOL method. RNA was purified by DNase I, and cDNA was synthesized by Roche reverse transcription reagent. A total of 20 μL of PCR reaction system was prepared using Roche fluorescent quantitative reagent, and PCR was started by running Bio-Rad real-time fluorescent PCR system. –ΔΔCT The data were analyzed by the method. The detected genes were OCT4, ΔNp63, KRT18, SOX1, Brachyury, FOXA2, KRT14, p75, Tuftelin, AMBN, AMELX, and the internal reference gene was GAPDH.
[0106] 3. Cell Immunofluorescence Staining
[0107] According to the induction scheme, samples were collected at different induction stages, cells were washed once with PBS, fixed with 10% neutral formalin buffer at room temperature for 10 min, treated with 0.2% Triton X-100 for 10 min, incubated with 5% bovine serum albumin (BSA) at room temperature for 30 min, incubated with anti-human keratin 14 (KRT14) and anti-human amelogenin (AMGN) primary antibodies, respectively, at 4°C overnight, incubated with specific fluorescent secondary antibodies the next day, protected from light at room temperature for 1 h, and finally incubated with DAPI at room temperature in the dark for 5 min, and photographed under a confocal microscope.
[0108] 4. Western Blot
[0109] According to the induction scheme, samples were collected at different induction stages, cells were washed with PBS, intracellular proteins were extracted with Blue Loading Buffer, SDS-PAGE electrophoresis was performed, and the target protein was transferred to PVDF membrane according to the protein marker indication, blocked with 5% skim milk at room temperature for 1 hour, incubated with primary antibody solution at 4°C overnight, incubated with corresponding HRP-labeled secondary antibody solution at room temperature for 1 hour the next day, incubated with chemical color development solution for 5 minutes, and exposed. Keratin 14 expression was detected in the induction stage of dental epithelial cells, and KRT14, AMGN, and AMBN expressions were detected in the induction stage of ameloblasts. The internal reference protein was β-actin.
[0110] 5. Optimization of surface ectoderm cell induction medium (medium I)
[0111] The results are as follows Figure 2 As shown, Figure 2 A in the figure is a schematic diagram of induction, comparing the culture medium I without adding SB431542 (SB43) and BMP4 (CON group), with only adding SB43 without adding BMP4 (SB43 group), and with adding SB43 and BMP4 at the same time (SB43+BMP4 group). Figure 2 B in the figure shows the cell morphology, and the scale bar is 200 μm. Figure 2 C in the figure is the expression of cell pluripotency (OCT4) and three germ layer markers (surface ectoderm: KRT18 and ΔNp63, neural ectoderm: SOX1, mesoderm: Brachyury, endoderm: FOXA2) evaluated by fluorescence quantitative PCR. Different letters (such as a, b) between groups indicate statistical significance (P<0.05; one-way ANOVA and Tukey test). The results showed that SB431542 and BMP4 synergistically promoted the expression of surface ectoderm markers, so medium I needed to contain both SB431542 and BMP4.
[0112] 6. Optimization of dental epithelial cell induction medium (medium II)
[0113] The results are as follows Figure 3 As shown, Figure 3 A in the figure is an induction schematic diagram. Different concentrations of LiCl are used in culture medium II to optimize the optimal concentration of LiCl. Figure 3 B shows cell morphology. The scale bar is 100 μm. Figure 3 C in the figure is quantitative PCR detection of gene expression of pluripotency (OCT4), proliferative epithelium (ΔNp63), dental epithelial cells (KRT14 and p75), and ameloblasts (Tuftelin and AMELX) markers. Different letters between groups (such as a, b) indicate statistically significant differences (p<0.05; one-way ANOVA and Tukey test). The results showed that 20mM LiCl was most conducive to the expression of dental epithelial markers. Figure 3 D in the figure shows immunofluorescence staining of keratin 14. The scale bar is 50 μm. Figure 3 E in the figure is the expression of keratin 14, a dental epithelial marker, detected by immunoblotting. The results show that 20 mM LiCl is most conducive to the expression of keratin 14. These results indicate that 20 mM LiCl is most conducive to the differentiation of dental epithelial cells, so 20 mM LiCl was added to medium II.
[0114] 7. Optimization of ameloblast induction medium (medium III)
[0115] Figure 4 A in the figure is a schematic diagram of ameloblast differentiation induction. Different concentrations of LiCl are used in culture medium III to optimize the optimal concentration of LiCl. Figure 4 B shows cell morphology. The scale bar is 100 μm. Figure 4 C in the figure shows the gene expression of pluripotency (OCT4), DEC (KRT14 and p75), and ameloblast (Tuftelin, AMELX, AMBN) markers detected by quantitative PCR. Different letters (such as a, b) between groups indicate statistically significant differences (p<0.05; one-way ANOVA and Tukey test). Figure 4 D in the figure is immunoblot, and 15mM LiCl is more conducive to the expression of enamel markers. Figure 4 E in Figure 1 is immunofluorescence staining of keratin 14 and AMGN. The scale bar is 50 μm. The white arrows indicate polarized ameloblasts, and 15 mM LiCl is more conducive to cell polarization. These results indicate that 15 mM LiCl is most conducive to ameloblast differentiation, so 15 mM LiCl was added to medium III.
[0116] The above-described embodiments only express several implementation methods of the present application, which is convenient for understanding the technical solution of the present application in detail, but it cannot be understood as a limitation on the scope of protection of the patent application. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present application, several deformations and improvements can be made, which all belong to the protection scope of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, the technicians in this field can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by the technicians in this field through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the protection scope of the claims attached to the present application. Therefore, the protection scope of the patent of the present application shall be based on the content of the attached claims, and the description and drawings can be used to explain the content of the claims.
Claims
1. A culture medium for inducing the directional differentiation of human pluripotent stem cells into ameloblasts, It is characterized in that It consists of medium I, medium II and medium III; The medium I is composed of DMEM / F12 medium, 15v / v%~20v / v% knockout serum replacement, 1.5mM~2.5mM L-glutamine, 0.8×10 -4 M~1.2×10 -4 M non-essential amino acids, 0.5v / v%~1.0v / v% penicillin-streptomycin dual antibody, 10μM~20μM SB431542 and 10ng / mL~25ng / mL BMP4 protein; The culture medium II is composed of DMEM / F12 culture medium, 15ng / mL~25ng / mL epidermal growth factor, 20ng / mL~30ng / mL basic fibroblast growth factor, 1.0v / v%~2.0v / v% B27 additive, 0.5v / v%~1.0v / v% penicillin-streptomycin double antibody, 10ng / mL~25ng / mL BMP4 protein, 0.5μM~1.0μM retinoic acid and 18mM~22mM lithium chloride; The culture medium III consists of DMEM / F12 basal culture medium, 8v / v%~12v / v% fetal bovine serum, 10mM~20mM β-glycerophosphate sodium, 45μg / mL~55μg / mL vitamin C, 1.5mM~2.5mM calcium chloride, 0.5v / v%~1.0v / v% penicillin-streptomycin dual antibody, 8ng / mL~12ng / mL epidermal growth factor, 2.5ng / mL~3.5ng / mL transforming growth factor β1 and 14mM~16mM lithium chloride.
2. A method for inducing the directed differentiation of human pluripotent stem cells into ameloblasts, It is characterized in that include: Human pluripotent stem cells are cultured using the culture medium for inducing directed differentiation of human pluripotent stem cells into ameloblasts as claimed in claim 1.
3. The method according to claim 2, It is characterized in that include: Human pluripotent stem cells were cultured in a basal medium for 0.5 to 1 day; then cultured in medium I for 2 to 2.5 days, then cultured in medium II for 2.5 to 3 days; finally cultured in medium III for 5 to 6 days to obtain ameloblasts; The basal culture medium contains mTeSR™1 medium and Y27632.
4. The method according to claim 3, It is characterized in that The human pluripotent stem cells further include the steps of pre-culture, digestion and passage before being cultured in the basic culture medium.
5. The method according to claim 3, It is characterized in that The human pluripotent stem cells are cultured in a basic medium for 2 to 8 generations, with a cell density of 60% to 70% and a cell differentiation ratio of <5%.
6. The method according to claim 4, It is characterized in that The digestion step includes: adding cell digestion solution, dissociating human pluripotent stem cells in the basic culture medium, and collecting cell suspension.
7. The method according to any one of claims 2 to 6, It is characterized in that The cultivation method has one or more of the following technical features: (1) Change the culture medium every 1 to 2 days during the culture process; (2) At 37°C, 5% CO 2 Cultivated under conditions of (3) Cultivating human pluripotent stem cells in a culture vessel coated with Matrigel; (4) The subculturing step includes inoculating the cell suspension into a culture vessel coated with matrix gel at a subculturing ratio of 1:10 to 1:15.
